Assistance Publique Hopitaux De Paris
Verified site
Creteil, France
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
People with active Crohn’s disease or ulcerative colitis have inflammation in the intestines that causes pain, diarrhea, and fatigue. The trial tests a medicine called infliximab, identified by the code name CT-P13, which can be given either as an injection under the skin (subcutaneous) or as a drip into a vein (intravenous). Both forms contain the same active ingredient and are meant to reduce the inflammation that drives the disease.
The purpose of the study is to show that the injection form works at least as well as the drip form in terms of pharmacokinetics, which means how the drug moves through the body, after six weeks of induction therapy. Participants receive the assigned form of the medicine at the start and then return for regular check‑ups over about six months. During these visits, doctors will look at blood samples to measure drug levels, ask about symptoms to see if there is a clinical response (meaning the symptoms improve) or clinical remission (meaning the symptoms are essentially gone), and test simple lab results called biomarker markers that show inflammation is decreasing. Safety will also be monitored by recording any side effects or reactions at the injection site.
The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.
9 criteria
14 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Creteil, France
Amiens, France
Neuilly-Sur-Seine, France
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
This is a biosimilar version of infliximab that is given by intravenous infusion. In the trial it is used as the comparator, meaning it represents the standard way the drug is usually given through a vein. Researchers look at how the medicine behaves in the body and how well it works when given this way.
This formulation of infliximab is provided in a pre‑filled syringe for subcutaneous injection. Participants inject the medicine just under the skin. In the study it is one of the test treatments, and the goal is to see if this easier, needle‑under‑the‑skin method works as well as the intravenous infusion.
This version of infliximab comes in a pre‑filled pen that also delivers the drug subcutaneously. Like the syringe, it allows the patient to inject the medicine under the skin. It is another test treatment in the trial, used to compare the safety, effectiveness, and how the drug is absorbed with the traditional intravenous infusion.
This medication is mixed with a liquid and given by intravenous infusion, meaning it goes directly into a vein. It is an approved biosimilar of infliximab and is widely used in clinical practice and research. It is mainly used to treat active Crohn’s disease and ulcerative colitis, two types of inflammatory bowel disease. The drug works by attaching to a protein called TNF‑alpha, which reduces inflammation, and it belongs to the class of monoclonal antibody anti‑TNF agents.
This version is a ready‑to‑use liquid that is injected under the skin (subcutaneous injection). It is an approved biosimilar of infliximab and is recognized in medical literature as an alternative to the intravenous form. It is used to treat active Crohn’s disease and ulcerative colitis. It blocks the inflammatory protein TNF‑alpha, acting as a monoclonal antibody anti‑TNF drug.
This product is a liquid that is self‑administered under the skin using a pre‑filled pen device. It is also an approved infliximab biosimilar and is documented in current medical sources. It is prescribed for patients with active Crohn’s disease or ulcerative colitis. Like the other forms, it binds to TNF‑alpha to lower inflammation and is classified as a monoclonal antibody anti‑TNF therapy.
chronic inflammation that can affect any part of the digestive tract, most often the end of the small intestine and the beginning of the colon. It usually starts with mild abdominal pain and diarrhea, and over time the inflammation can cause thickening of the intestinal wall, leading to narrowing, fistulas, or abscesses. Symptoms may come and go, with periods of worsening followed by calmer phases.
long‑lasting inflammation limited to the lining of the large intestine and rectum. It often begins with frequent loose stools that may contain blood, and the inflammation can spread upward along the colon. As the disease continues, the colon wall becomes irritated and may develop ulcers, causing increased urgency and discomfort. Flare‑ups can alternate with times of fewer symptoms.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.